Boston Scientific instigates TAXUS Liberte Stent study

Boston Scientific has revealed that the first participants have enrolled in its TAXUS Liberte Stent clinical trial.

The study will evaluate real-world clinical outcomes data for the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.

It will be examined in combination with a dual antiplatelet therapy drug regimen that includes the new antiplatelet treatment Effient and aspirin.

Eli Lilly and Daiichi Sankyo, which manufacturers Effient, are co-sponsors of the research.

The primary endpoint of the research is to reduce the rate of cardiac deaths or incidents of myocardial infarction after a period of 12 months.

Keith Dawkins, senior vice-president and associate chief medical officer at Boston Scientific, commented: “The TAXUS Liberte post-approval study will allow us to further assess the second-generation TAXUS Liberte Stent […] in a variety of complex lesions.”

In other Boston Scientific news, the firm appointed Nelda Connors to its board of directors last month – the current president of the electrical and metal products division of Tyco International.